

Spero R Cataland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1905714/publications.pdf>

Version: 2024-02-01

116
papers

4,681
citations

94269

37
h-index

102304

66
g-index

119
all docs

119
docs citations

119
times ranked

3875
citing authors

#	ARTICLE	IF	CITATIONS
1	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2019, 380, 335-346.	13.9	625
2	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2016, 374, 511-522.	13.9	480
3	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. <i>American Journal of Kidney Diseases</i> , 2016, 68, 84-93.	2.1	230
4	Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. <i>Blood</i> , 2003, 101, 425-432.	0.6	221
5	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2496-2502.	1.9	188
6	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2486-2495.	1.9	142
7	Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. <i>Blood</i> , 2014, 123, 3733-3738.	0.6	130
8	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. <i>Kidney International</i> , 2020, 97, 1287-1296.	2.6	123
9	How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. <i>Blood</i> , 2014, 123, 2478-2484.	0.6	115
10	Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. <i>Haematologica</i> , 2010, 95, 1555-1562.	1.7	114
11	Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. <i>British Journal of Haematology</i> , 2008, 141, 651-658.	1.2	113
12	Redefining outcomes in immune TTP: an international working group consensus report. <i>Blood</i> , 2021, 137, 1855-1861.	0.6	103
13	Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. <i>Journal of Clinical Medicine</i> , 2021, 10, 536.	1.0	94
14	A Phase I Biological Study of MG98, an Oligodeoxynucleotide Antisense to DNA Methyltransferase 1, in Patients with High-Risk Myelodysplasia and Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2008, 14, 2444-2449.	3.2	83
15	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. <i>Blood</i> , 2020, 136, 2103-2117.	0.6	82
16	Venous Thromboembolic Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1402-1429.	2.3	80
17	None of the above: thrombotic microangiopathy beyond TTP and HUS. <i>Blood</i> , 2017, 129, 2857-2863.	0.6	73
18	An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2007, 136, 146-149.	1.2	72

#	ARTICLE	IF	CITATIONS
19	Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2012, 87, 430-432.	2.0	71
20	Effect of Blood Sampling, Processing, and Storage on the Measurement of Complement Activation Biomarkers. <i>American Journal of Clinical Pathology</i> , 2015, 143, 558-565.	0.4	69
21	Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. <i>Blood Advances</i> , 2017, 1, 2075-2082.	2.5	61
22	Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2019, 381, 92-94.	13.9	59
23	Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2011, 86, 87-89.	2.0	57
24	Ciclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. <i>British Journal of Haematology</i> , 2007, 139, 486-493.	1.2	55
25	Myeloid Growth Factors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1266-1290.	2.3	53
26	Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. <i>Kidney International Reports</i> , 2019, 4, 1568-1576.	0.4	50
27	Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. <i>Blood Advances</i> , 2018, 2, 2619-2628.	2.5	49
28	Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. <i>Intensive Care Medicine</i> , 2019, 45, 1518-1539.	3.9	47
29	Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1925-1927.	1.9	45
30	The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. <i>Blood</i> , 2018, 132, 903-910.	0.6	45
31	Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 479-484.	1.9	45
32	The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. <i>British Journal of Haematology</i> , 2012, 157, 501-503.	1.2	43
33	Diagnosis and management of complement mediated thrombotic microangiopathies. <i>Blood Reviews</i> , 2014, 28, 67-74.	2.8	43
34	Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies. <i>European Journal of Internal Medicine</i> , 2013, 24, 486-491.	1.0	42
35	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. <i>Blood Advances</i> , 2021, 5, 2137-2141.	2.5	39
36	Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2008, 83, 911-915.	2.0	38

#	ARTICLE	IF	CITATIONS
37	Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. <i>Transfusion</i> , 2015, 55, 18-24.	0.8	38
38	Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease. <i>Haematologica</i> , 2006, 91, 1329-35.	1.7	38
39	Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation. <i>Annals of Hematology</i> , 2013, 92, 845-846.	0.8	35
40	Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. <i>American Journal of Hematology</i> , 2010, 85, 976-977.	2.0	32
41	Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. <i>Thrombosis Research</i> , 2017, 151, 51-56.	0.8	32
42	ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome. <i>Haematologica</i> , 2011, 96, 1521-1527.	1.7	30
43	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. <i>Kidney International Reports</i> , 2021, 6, 1603-1613.	0.4	29
44	Immunotherapy for thrombotic thrombocytopenic purpura. <i>Current Opinion in Hematology</i> , 2005, 12, 359-363.	1.2	27
45	Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. <i>European Journal of Haematology</i> , 2009, 83, 559-564.	1.1	26
46	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2503-2512.	1.9	25
47	Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. <i>American Journal of Hematology</i> , 2020, 95, E76-E77.	2.0	24
48	Novel therapies in thrombotic thrombocytopenic purpura. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 19-26.	1.0	22
49	ADAMTS13 activity and the risk of thrombotic thrombocytopenic purpura relapse in pregnancy. <i>British Journal of Haematology</i> , 2011, 153, 277-279.	1.2	21
50	Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission. <i>Blood Advances</i> , 2022, 6, 1264-1270.	2.5	20
51	Profound neurological injury in a patient with atypical hemolytic uremic syndrome. <i>Annals of Hematology</i> , 2013, 92, 557-558.	0.8	19
52	TTP disease course is independent of myeloma treatment and response. <i>American Journal of Hematology</i> , 2010, 85, 304-306.	2.0	17
53	Preliminary Experience with a New Chemotherapy Regimen for Adults with Acute Lymphoblastic Leukemia. <i>Leukemia and Lymphoma</i> , 2001, 41, 297-307.	0.6	15
54	Incorporation of Alemtuzumab into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL) Is Feasible: A Phase I/II Study from the Cancer and Leukemia Group B (CALGB 10102).. <i>Blood</i> , 2005, 106, 145-145.	0.6	15

#	ARTICLE	IF	CITATIONS
55	Long-term, subclinical cardiac and renal complications in patients with multiple relapses of thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2010, 149, 623-625.	1.2	14
56	Headache prevalence following recovery from TTP and aHUS. <i>Annals of Hematology</i> , 2015, 94, 1473-1476.	0.8	14
57	Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. <i>Clinical Colorectal Cancer</i> , 2017, 16, e119-e122.	1.0	14
58	No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: The experience from the Ohio State University Registry. <i>American Journal of Hematology</i> , 2018, 93, E73-E75.	2.0	12
59	Eculizumab deposits in vessel walls in thrombotic microangiopathy. <i>Kidney International</i> , 2019, 96, 761-768.	2.6	12
60	Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry. <i>Kidney International Reports</i> , 2020, 5, 1161-1171.	0.4	12
61	SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura. <i>Blood</i> , 2022, 139, 2570-2573.	0.6	12
62	Validation of claims-based diagnostic codes for idiopathic thrombotic thrombocytopenic purpura in a commercially-insured population. <i>Thrombosis and Haemostasis</i> , 2010, 103, 1203-1209.	1.8	11
63	Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2021, 96, 1587-1594.	2.0	9
64	Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab. <i>Blood</i> , 2019, 134, 1099-1099.	0.6	9
65	Clinical relapse of immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12658.	1.0	9
66	Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 567-576.	0.5	8
67	Practical Issues in ADAMTS13 Testing and Emerging Therapies in Thrombotic Thrombocytopenic Purpura. <i>Seminars in Hematology</i> , 2011, 48, 242-250.	1.8	7
68	Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2017, 130, LBA-1-LBA-1.	0.6	7
69	Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2020, 189, e18-e20.	1.2	6
70	Cardiovascular Disease Is a Leading Cause of Death in Thrombotic Thrombocytopenic Purpura (TTP) Survivors. <i>Blood</i> , 2020, 136, 22-23.	0.6	6
71	Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 437-444.	0.9	5
72	Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 319-324.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. Case Reports in Hematology, 2015, 2015, 1-3.	0.3	5
74	Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy. European Heart Journal - Case Reports, 2020, 4, 1-6.	0.3	4
75	A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura. Blood, 2016, 128, 133-133.	0.6	4
76	Antibody Therapy of Acute and Chronic Leukemias. Current Pharmaceutical Biotechnology, 2001, 2, 357-367.	0.9	4
77	Diagnostic and Prognostic Values Of ADAMTS13 Activity Measured During Daily Plasma Exchange Therapy In Patients With Acquired TTP. Blood, 2013, 122, 1079-1079.	0.6	4
78	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3739-3739.	0.6	3
79	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. Blood, 2018, 132, 3744-3744.	0.6	3
80	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. Blood, 2018, 132, 1142-1142.	0.6	3
81	Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy. Blood, 2019, 134, 1098-1098.	0.6	3
82	Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS). Blood, 2013, 122, 2179-2179.	0.6	3
83	3 Rs: rituximab, remission, relapse. Blood, 2011, 118, 1711-1712.	0.6	2
84	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. Bone Marrow Transplantation, 2019, 54, 913-916.	1.3	2
85	SO054ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	2
86	In vitro diagnostics for the medical dermatologist. Part II: Hypercoagulability tests. Journal of the American Academy of Dermatology, 2021, 85, 301-310.	0.6	2
87	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 373-373.	0.6	2
88	Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations. Blood, 2019, 134, 90-90.	0.6	2
89	Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study. Blood, 2019, 134, 931-931.	0.6	2
90	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen. Blood, 2019, 134, 2365-2365.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. <i>Blood</i> , 2019, 134, 2366-2366.	0.6	2
92	African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2019, 134, 1066-1066.	0.6	2
93	Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies. <i>Blood</i> , 2021, 138, 769-769.	0.6	2
94	Eculizumab Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 438-439.	2.0	1
95	FP250FACIT-FATIGUE SCORES IN ADULT PATIENTS AT ENROLLMENT INTO THE GLOBAL AHUS REGISTRY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i114-i114.	0.4	1
96	Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. <i>Blood</i> , 2019, 134, 4908-4908.	0.6	1
97	Myocardial Ischemia in Patients with Sickle Cell Disease: A Retrospective Review. <i>Blood</i> , 2015, 126, 2189-2189.	0.6	1
98	Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2020, 136, 8-9.	0.6	1
99	Common clinical variables predict warfarin maintenance dose and therapeutic resistance. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 101-101.	1.0	0
100	Clinical utility of complement biomarkers in the diagnosis and treatment of acute thrombotic microangiopathies. <i>British Journal of Haematology</i> , 2014, 167, 697-698.	1.2	0
101	Cyclosporine Alone for the Treatment of Early Recurrences of TTP.. <i>Blood</i> , 2005, 106, 1236-1236.	0.6	0
102	A Rapid Test for the Diagnosis of Thrombotic Thrombocytopenic Purpura Using SELDI-TOF-Mass Spectrometry.. <i>Blood</i> , 2005, 106, 2660-2660.	0.6	0
103	Evaluation of Qualitative Platelet Disorders in Patients with Hemophilia.. <i>Blood</i> , 2005, 106, 3987-3987.	0.6	0
104	Myocardial Ischemia without Coronary Artery Obstruction in Patients with Sickle Cell Disease.. <i>Blood</i> , 2005, 106, 3180-3180.	0.6	0
105	Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.. <i>Blood</i> , 2005, 106, 1235-1235.	0.6	0
106	Low ADAMTS13 Activity in Clinical Remission Predicts the Risk of TTP Relapses.. <i>Blood</i> , 2007, 110, 4018-4018.	0.6	0
107	Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor in Early Remission Are Associated with a Higher Probability of TTP Exacerbation.. <i>Blood</i> , 2008, 112, 2299-2299.	0.6	0
108	Comparison of Clinical Outcomes Between Initial and Relapsed Events of Thrombotic Thrombocytopenic Purpura In a Large TTP Cohort.. <i>Blood</i> , 2010, 116, 1439-1439.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Longitudinal Analysis of VWF Multimerization Patterns In a well-defined TTP Cohort. Blood, 2010, 116, 4308-4308.	0.6	0
110	Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS. Blood, 2013, 122, 3552-3552.	0.6	0
111	Prospective Analysis of Complement Activation in Allogeneic Transplant Recipients and Correlation with Transplant Associated Thrombotic Microangiopathy (TA-TMA) and Acute Graft Versus Host Disease (aGVHD). Blood, 2018, 132, 4572-4572.	0.6	0
112	A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura. Blood, 2019, 134, 2377-2377.	0.6	0
113	Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study. Blood, 2019, 134, 1093-1093.	0.6	0
114	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. Blood, 2021, 138, 2080-2080.	0.6	0
115	Preferences for Accessing Patient Reported Outcomes and Health Information Among Thrombotic Thrombocytopenic Purpura Survivors. Blood, 2021, 138, 3039-3039.	0.6	0
116	Recent advances in the management of atypical hemolytic uremic syndrome. Clinical Advances in Hematology and Oncology, 2012, 10, 537-9.	0.3	0